Core Viewpoint - The company, Tigermed (03347.HK), reported a revenue increase of 3.5% year-on-year for the fiscal year 2025, with significant profit growth driven by the recovery of the domestic biopharmaceutical industry and increased demand for clinical research outsourcing services [1][2]. Group 1: Financial Performance - Revenue rose from RMB 6.603 billion to RMB 6.833 billion, reflecting a year-on-year growth of 3.5% [1] - Profit increased by 79.8% to RMB 0.805 billion during the reporting period [1] - Profit attributable to shareholders surged by 119.2% to RMB 0.888 billion [1] - Basic earnings per share reached RMB 1.04, with a proposed final dividend of RMB 1.26 per 10 shares [1] Group 2: Industry Trends - The domestic biopharmaceutical industry is recovering, contributing to sustained demand for clinical research outsourcing services [1] - The clinical research outsourcing industry is undergoing further consolidation, leading to improved competition [1] - The company is focusing on developing business opportunities from both domestic pharmaceutical companies and large multinational pharmaceutical firms [1] Group 3: Order Growth - New orders increased significantly, with net new orders amounting to RMB 10.2 billion, representing a year-on-year growth of 20.6% [2] - The average price of new orders has stabilized and is expected to return to a growth trend in 2026 [2] - The total amount of contracts to be executed reached RMB 18.2 billion, marking a year-on-year increase of 15.4% [2]

格隆汇3月30日丨泰格医药(03347.HK)发布2025年度业绩。报告期间，收入由同期的人民币66.03亿元增 至人民币68.33亿元，同比增长3.5%。期内利润增加79.8%至报告期间的人民币8.05亿元。公司拥有人应 占利润增加119.2%至报告期间的人民币8.88亿元。基本每股盈利1.04元，董事会建议宣派截至2025年12 月31日止年度的末期股息每10股人民币1.26元(含税)。 2025年，随着国内生物医药行业的恢复，以及中国创新药研发产业链进一步融入全球版图，临床研究外 包服务需求延续了复苏态势。同时，2025年临床研究外包行业进一步整合，行业竞争趋於良性。公司商 务发展(BD)部门及全体员工一方面继续深耕国内优质客户，持续开发临床研发及相关业务订单，尤其 是来自国内药企和优质生物科技公司的订单；另一方面也积极开拓来自大型跨国药企的业务机遇。 报告期内，新订单按年增长较2024年有所加快，净新增订单（新签订单剔除取消订单後）金额为人民币 102亿元，同比增长20.6%。2025年，新订单的平均单价已经企稳，并有望在2026年重回增长态势。截 至报告期末，待执行合同金额达人民币182亿元，同比增 ...

Core Viewpoint - The company, Tigermed, forecasts a revenue range of RMB 6.66 billion to RMB 7.68 billion for the year 2025, indicating a return to growth after a previous decline [1][3]. Financial Performance - The non-recurring gains attributable to shareholders are expected to be between RMB 500 million and RMB 740 million, a significant increase from the previous year's loss of RMB 449.75 million, resulting in a net increase of RMB 949.75 million to RMB 1.18975 billion [2]. - The net profit attributable to shareholders, excluding non-recurring gains, is projected to be between RMB 330 million and RMB 490 million, a decrease of 43% to 61% compared to the previous year's profit of RMB 854.90 million [5]. - The net cash flow from operating activities is estimated to be between RMB 1.1 billion and RMB 1.3 billion, reflecting a slight increase from RMB 1.097 billion in the previous year [4]. Market Position and Industry Trends - The company maintains its leading position in China's clinical research outsourcing (CRO) industry, with a market share that remains the highest according to Frost & Sullivan [3]. - The demand for clinical research outsourcing services continues to recover, driven by the resurgence of the innovative drug industry in China and the integration of the clinical research supply chain into the global landscape [3]. - The company has seen a good growth in new orders, with net new orders expected to be between RMB 9.5 billion and RMB 10.5 billion, compared to RMB 8.42 billion in the previous year [3]. Operational Insights - The company has implemented risk screening measures to identify potential risks and adjust fair value accordingly, which has contributed to the increase in investment income and fair value changes from non-current financial assets [2]. - The average price of new orders has stabilized after a decline due to competitive pressures in the clinical research outsourcing industry [5].

Core Viewpoint - The company, Tigermed, forecasts a net profit of RMB 330 million to RMB 490 million for the year 2025, excluding non-recurring gains and losses, indicating a significant recovery in its financial performance compared to the previous year [1]. Financial Performance - The non-recurring gains and losses attributable to shareholders are expected to be between RMB 500 million and RMB 740 million, a substantial increase from the previous year's loss of RMB 449.75 million, resulting in a net increase of RMB 949.75 million to RMB 1.18975 billion [2]. - The company's operating revenue is projected to be between RMB 6.66 billion and RMB 7.68 billion, reflecting a year-on-year increase of 1% to 16%, marking a return to growth [3]. - The net cash flow from operating activities is estimated to be between RMB 1.1 billion and RMB 1.3 billion, showing a slight increase from RMB 1.097 billion in the previous year [4]. Order Growth and Market Position - The company anticipates new net orders in the range of RMB 9.5 billion to RMB 10.5 billion for 2025, compared to RMB 8.42 billion in 2024, indicating strong growth in order intake [3]. - Tigermed maintains its leading position in the Chinese clinical research outsourcing (CRO) industry, with its market share ranked first according to Frost & Sullivan [3]. Profitability and Challenges - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be between RMB 330 million and RMB 490 million, a decrease of 43% to 61% compared to the previous year's profit of RMB 854.9 million [5]. - Factors contributing to the decline in profit include cancellations of historical orders and increased operational costs due to team expansions in response to industry demand recovery [5]. - The average price of new orders has stabilized after a decline in recent years, which had previously impacted profit margins [5]. Recent Quarterly Performance - For the first three quarters of 2025, the company's main revenue was RMB 5.026 billion, a slight decrease of 0.82% year-on-year, while the net profit attributable to shareholders was RMB 1.02 billion, an increase of 25.45% [6]. - The third quarter alone saw main revenue of RMB 1.775 billion, a year-on-year increase of 3.86%, with a net profit of RMB 637 million, up 98.73% year-on-year [6].

Group 1 - The core point of the article is that Norsg (sz301333) reached its daily limit up on January 13, 2026, with a price of 76.48 yuan, representing a 20.01% increase, and a total market capitalization of 7.387 billion yuan [1] Group 2 - The reasons for Norsg's limit up include governance optimization, performance growth, and effective capital utilization. The company announced a comprehensive governance structure optimization, including board structure adjustments and the addition of independent directors, which enhances decision-making and transparency [2] - The company utilized 140 million yuan of raised funds to supplement its working capital, improving capital efficiency and reducing financial costs, signaling good management and development prospects [2] - For Q3 2025, the company reported impressive operating performance with a revenue increase of 24.48%, net profit growth of 32.98%, and a 52.69% rise in non-recurring net profit, indicating strong business momentum [2] - As a provider of full-chain clinical research outsourcing services for global pharmaceutical and medical device companies, the company benefits from the growth of the pharmaceutical industry [2] - From a technical perspective, the stock may have attracted investor interest due to positive signals such as MACD crossovers and price breakthroughs, alongside a sector-wide positive performance [2]

Core Insights - The company reported a revenue of 609 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2.59% [1] - Net profit reached 87.38 million yuan, showing a year-on-year growth of 20.92% [1] - The company attributed its performance to ongoing refined operational management measures [1] Company Overview - The company is a data-driven clinical research service provider, focusing on the management of clinical trial site organizations (SMO) [1] - It has served over 960 clinical trial institutions and has the capability to cover more than 1,300 institutions across over 200 cities in China [2] - As of the reporting period, the company had undertaken over 4,200 international and domestic SMO projects, with 2,538 projects currently in execution [2] Market Demand and Performance - The company noted a positive recovery in industry and client demand, with a significant increase in inquiry volume and new contracts [1] - The new signed contracts (excluding tax) amounted to 600 million yuan, reflecting a year-on-year increase of 40.12% [2] - The company’s backlog of contracts (excluding tax) stood at 1.998 billion yuan, up 9.45% year-on-year as of June 2025 [2] Industry Landscape - The SMO industry in China is entering a new development phase, with leading SMO companies expanding their client resources, professional talent, and research institution coverage [3] - There is an increasing concentration in the industry as smaller SMO companies begin to exit the market, benefiting larger firms with stronger technical barriers and brand influence [3]